• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Aaron Lorenzo

Aaron Lorenzo

Articles

ARTICLES

Roche Licenses Rights To IL-15 Preclinical Program From Cardion

July 23, 2003
By Aaron Lorenzo
Hoffmann-La Roche Inc. could find itself paying up to $90 million or more for a preclinical research program with transplant rejection and rheumatoid arthritis applications. (BioWorld Today)
Read More

Onyx Raises $71M In Public Offering Of 5 Million Shares

July 23, 2003
By Aaron Lorenzo

Roche Licenses Rights To IL-15 Preclinical Program From Cardion

July 23, 2003
By Aaron Lorenzo
Hoffmann-La Roche Inc. could find itself paying up to $90 million or more for a preclinical research program with transplant rejection and rheumatoid arthritis applications. (BioWorld Today)
Read More

ILEX Proposes Public Offering That Could Gross $115.9 Million

July 22, 2003
By Aaron Lorenzo

Praecis Still Expects Plenaxis Approval Despite 3-Month Delay

July 22, 2003
By Aaron Lorenzo
Praecis Pharmaceuticals Inc. continues to expect regulatory approval for Plenaxis despite an FDA decision to delay action on the new drug application by three months. (BioWorld Today)
Read More

Praecis Still Expects Plenaxis Approval Despite 3-Month Delay

July 22, 2003
By Aaron Lorenzo
Praecis Pharmaceuticals Inc. continues to expect regulatory approval for Plenaxis despite an FDA decision to delay action on the new drug application by three months. (BioWorld Today)
Read More

ILEX Proposes Public Offering That Could Gross $115.9 Million

July 22, 2003
By Aaron Lorenzo

Vicuron Grosses $83.1M Through Public Offering Of Common Stock

July 21, 2003
By Aaron Lorenzo
Vicuron Pharmaceuticals Inc. priced a public offering of stock that raised $83.1 million in gross proceeds. (BioWorld Today)
Read More

Vicuron Grosses $83.1M Through Public Offering Of Common Stock

July 21, 2003
By Aaron Lorenzo
Vicuron Pharmaceuticals Inc. priced a public offering of stock that raised $83.1 million in gross proceeds. (BioWorld Today)
Read More

Tercica Reels In $44M In Series B Funding For IGF-1 Product Launch

July 18, 2003
By Aaron Lorenzo
View All Articles by Aaron Lorenzo

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 28, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 28, 2025.
  • Boston Scientific Acurate Prime Aortic Valve System

    In TAVR setback, Boston Sci pulls plug on Acurate valves

    BioWorld MedTech
    Boston Scientific Corp. reported the latest setback in its transcatheter aortic valve replacement (TAVR) aspirations with the news that it is officially...
  • 3d rendering of bispecific antibodies

    Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody

    BioWorld
    Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 27, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe